VAERS Explorer
Back to explore

Report #2884607

Received Feb 6, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
—
Recovered
Not recovered
Vaccinated
Jan 28, 2026
Onset
Jan 29, 2026
Days to onset
1
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1UNK—

Symptoms (2)

HeadacheNight sweats

Symptom narrative

Night sweats; Headache; This non-serious case was reported by a consumer and described the occurrence of headache in a 58-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 28-JAN-2026, the patient received the 1st dose of Shingrix. On 29-JAN-2026, 1 days after receiving Shingrix, the patient experienced headache (Verbatim: Headache). On 31-JAN-2026, the patient experienced night sweat (Verbatim: Night sweats). The outcome of the headache and night sweat were not resolved. It was unknown if the reporter considered the headache and night sweat to be related to Shingrix. It was unknown if the company considered the headache and night sweat to be related to Shingrix. Additional Information: GSK receipt date:02-FEB-2026 Patient stated that symptoms were not treated. It was also stated that side effects would prevent patient from taking 2nd dose. The batch number was not provided and a request for this information has been made.